Pricing Log in Create free account
Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

45.30 0.76 +1.71%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alkermes plc 8-K filed Jan 6, 2026

Period ended Jan 6, 2026 · Filed · accepted 7:06 AM ET · Document on sec.gov · Filing index

7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov